Solventum Stock On Fire: Up 13% With 7-Day Winning Streak
Solventum (SOLV) – a healthcare company developing and commercializing critical patient solutions – hit a 7-day winning streak, with cumulative gains over this period amounting to 13%. The company’s market cap has surged by about $1.5 Bil over the last 7 days and currently stands at $13 Bil.
Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
But here is the interesting part. You are reading about this 13% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Inside SMH: The Few Stocks Driving Your Semiconductor Returns
- Is Qualcomm Stock A Bet On AI’s Future Or A Hostage To The Smartphone’s Present?
- The Quiet Contract Shift Before Western Digital Stock’s Loud Re-Rating
- Beyond the Quarter: What Could Power The Next Leg Of Broadcom Stock’s Climb
- Booking Stock Testing Price Floor – Buy Now?
- Ciena’s AI Story Is Soaring. Is Ubiquiti The Smarter Play?
The following table summarizes the return for SOLV stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SOLV | S&P 500 |
|---|---|---|
| 1D | 1.3% | -0.2% |
| 7D (Current Streak) | 12.7% | 2.4% |
| 1M (21D) | 11.4% | 7.5% |
| 3M (63D) | -6.7% | 6.6% |
| YTD 2026 | -5.2% | 8.1% |
| 2025 | 20.0% | 16.4% |
| 2024 | 23.3% | |
| 2023 | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 45 S&P constituents with 3 days or more of consecutive gains and 86 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 34 | 40 |
| 4D | 3 | 39 |
| 5D | 5 | 2 |
| 6D | 0 | 2 |
| 7D or more | 3 | 3 |
| Total >=3 D | 45 | 86 |
Key Financials for Solventum (SOLV)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $8.3 Bil | $8.3 Bil |
| Operating Income | $1.0 Bil | $632.0 Mil |
| Net Income | $479.0 Mil | $1.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $2.0 Bil | $2.0 Bil |
| Operating Income | $93.0 Mil | $79.0 Mil |
| Net Income | $63.0 Mil | $13.0 Mil |
While SOLV stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.